Lung cancer is the leading cause of cancer-related deaths worldwide. It exhibits, at the
mesoscopic scale, phenotypic characteristics that are generally indiscernible to the human …

A substantial number of studies have reported the development of gene expression–based
prognostic signatures for lung cancer. The ultimate aim of such studies should be the …

Background Current clinical therapy of non-small cell lung cancer depends on histo-
pathological classification. This approach poorly predicts clinical outcome for individual …

Purpose The JBR. 10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in
early-stage non–small-cell lung cancer (NSCLC). We hypothesized that expression profiling …

Background The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is
generally attributable to metastatic disease undetected at complete resection. Management …

Purpose: To assess the impact of cell type, age, and gender in addition to pathologic tumor,
node, metastasis (TNM) stage in surgically managed stage I-IIIA non-small cell lung cancer …

Background While several molecular markers of bladder cancer prognosis have been
identified, the limited value of current prognostic markers has created the need for new …

Acidic tissue microenvironment contributes to tumor progression via multiple effects
including the activation of angiogenic factors and proteases, reduced cell-cell adhesion …

About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will
recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs …

Lung adenocarcinoma (LUAD), the most common non‐small‐cell lung cancer, is
characterized by a dense lymphocytic infiltrate, which indicates that the immune system …